Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Serodus ASA (SER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013362
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Serodus ASA (Serodus) is a drug development company that focuses on the development of products for unmet medical needs in areas such as diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephropathy; SER130AMI, an interleukin-4 agonist for acute myocardial infarction; SER100PH, for group I or IV pulmonary hypertension; and SER100TRISH, an opioid receptor like-1 (ORL-1, nociceptin) receptor partial agonist, for therapy resistant isolated systolic hypertension, besides SER140T2D, an interleukin-1 receptor antagonist in preclinical phase for Type 2 Diabetes. It enters into licensing arrangements and collaborates with biotech companies and universities to develop its product pipeline. Serodus is headquartered in Oslo, Norway.

Serodus ASA (SER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Serodus ASA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Serodus Raises US$0.09 Million In Venture Financing 10
Licensing Agreements 11
Evolva And Serodus Enter Into Licensing Agreement For EV-077 11
Equity Offering 12
Serodus Raises USD1.2 Million in Private Placement of Shares 12
Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13
Serodus Completes Public Offering of Shares for USD1.71 Million 14
Serodus Completes Private Placement Of Shares For US$4.9 Million 15
Serodus Completes IPO Of US$0.7 Million 16
Acquisition 18
Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18
Serodus Completes Acquisition of Phlogo for USD0.9 Million 19
Serodus ASA – Key Competitors 20
Serodus ASA – Key Employees 21
Serodus ASA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Feb 27, 2017: Serodus: Results for Q4-2016 23
Oct 27, 2016: Serodus: Results Q3 2016 24
Aug 18, 2016: Serodus Reports Q2-2016 Interim Results 29
Apr 27, 2016: Serodus : Q1-2016 Interim results 31
Feb 17, 2016: Serodus: Q4-2015 Interim results 32
Corporate Communications 33
Jun 27, 2016: Serodus: Changes in the Board of Directors 33
Clinical Trials 34
Feb 03, 2016: Serodus announces completion of patient enrollment of the first cohort in Phase 2a clinical trial of SER150 in patients with Diabetic Nephropathy 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Serodus ASA, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Serodus ASA, Deals By Therapy Area, 2011 to YTD 2017 8
Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Serodus Raises US$0.09 Million In Venture Financing 10
Evolva And Serodus Enter Into Licensing Agreement For EV-077 11
Serodus Raises USD1.2 Million in Private Placement of Shares 12
Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13
Serodus Completes Public Offering of Shares for USD1.71 Million 14
Serodus Completes Private Placement Of Shares For US$4.9 Million 15
Serodus Completes IPO Of US$0.7 Million 16
Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18
Serodus Completes Acquisition of Phlogo for USD0.9 Million 19
Serodus ASA, Key Competitors 20
Serodus ASA, Key Employees 21
Serodus ASA, Subsidiaries 22

★海外企業調査レポート[Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lepu Medical Technology (Beijing) Co Ltd (300003)-製薬・医療分野:企業M&A・提携分析
    Summary Lepu Medical Technology (Beijing) Co Ltd (Lepu Medical) is a medical device company that designs, develops, and distributes medical equipments. The company’s products include interventional cardiology products, cardiac in vitro diagnosis products, occlusion devices, pacemaker, angiographic e …
  • GDI Integrated Facility Services Inc (GDI):企業の財務・戦略的SWOT分析
    Summary GDI Integrated Facility Services Inc (GDI), formery Medwell Capital Corp is a commercial facility service provider. The company’s services include cleaning, food plant sanitation, technical trade services and energy management, healthcare sanitation, hotel support, event support and disaster …
  • BP Plc (BP.)-エネルギー分野:企業M&A・提携分析
    Summary BP p.l.c. (BP) is an integrated oil and gas company. It provides fuel, energy, lubricants and petrochemicals to its customers. Its upstream activities include oil and natural gas exploration, field development and production; and midstream operations include transportation, and marketing and …
  • Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • Snyder’s-Lance, Inc.:戦略・SWOT・企業財務分析
    Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Snyder's-Lance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Alliance Pharma Plc (APH):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliance Pharma Plc (Alliance) is a specialty pharmaceutical company. It focuses on acquisition, licensing, registration and marketing of pharmaceutical products. It promotes acquired and licensed prescription products across various therapeutic categories such as dermatology, central nervou …
  • Basilea Pharmaceutica Ltd (BSLN):企業の財務・戦略的SWOT分析
    Summary Basilea Pharmaceutica Ltd (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company’s products address increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial …
  • EPAM Systems Inc (EPAM):企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Brookfield Infrastructure Partners LP:企業のM&A・事業提携・投資動向
    Brookfield Infrastructure Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brookfield Infrastructure Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Hydro One Ltd (H):企業の財務・戦略的SWOT分析
    Hydro One Ltd (H) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Absher Construction Company:企業の戦略・SWOT・財務分析
    Absher Construction Company - Strategy, SWOT and Corporate Finance Report Summary Absher Construction Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Coca-Cola Bottling Co. Consolidated (COKE):企業の財務・戦略的SWOT分析
    Coca-Cola Bottling Co. Consolidated (COKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • US Energy Development Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary US Energy Development Corp (US Energy) is an independent oil and gas corporation that explores and produces crude oil and natural gas. The corporation offers services such as horizontal drilling, natural gas storage, hydraulic fracturing, geologic and engineering reviews, drilling and comple …
  • Alviva Holdings Ltd (AVV):企業の財務・戦略的SWOT分析
    Alviva Holdings Ltd (AVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Norwegian Energy Company ASA (NOR):石油・ガス:M&Aディール及び事業提携情報
    Summary Norwegian Energy Company ASA (Noreco) is an oil and gas company that offers exploration and development services. The company explores, produces and develops oil, gas, and natural gas liquids deposit properties. It operates through ongoing and planned exploration wells such as PL616 Haribo a …
  • Diebold Nixdorf, Incorporated:企業の戦略・SWOT・財務情報
    Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • ProSiebenSat.1 Media AG (PSM):企業の財務・戦略的SWOT分析
    ProSiebenSat.1 Media AG (PSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Kot Addu Power Co Ltd:発電所・企業SWOT分析
    Kot Addu Power Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • Misawa Homes Co., Ltd.:戦略・SWOT・企業財務分析
    Misawa Homes Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Misawa Homes Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Genalyte Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genalyte Inc (Genalyte) is a lab testing service provider. The company’s services include data analysis, phlebotomist for blood draw, integration with existing emr, phlebotomist for blood draw, applications for test order and results review and clinical lab scientist. It provides instruments …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆